CMS' obstetric G-codes cause confusion, perimenopause uncertainty, Zuranolone real-world data

Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, July 13, to Friday, July 17, 2026) and click on each link to read and watch anything you may have missed.

CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition

The Centers for Medicare & Medicaid Services (CMS) is proposing new HCPCS G-codes for 2027 that would preserve the existing global payment structure for maternity services, drawing concern from the American College of Obstetricians and Gynecologists (ACOG), which warns the move could create a dual billing system that increases administrative burden and worsens obstetric care disparities.

Click here for the full article.

Clinical and surgical diagnosis of endometriosis, with Heather Appelbaum, MD

Recognizing when to make a pattern-based clinical diagnosis of endometriosis, rather than defaulting to surgical confirmation, can help clinicians intervene sooner and relieve patients' symptoms more quickly, according to Heather Appelbaum, MD, FACOG, director of Pediatric and Adolescent Gynecology at K. Hovnanian Children's Hospital at Hackensack Meridian Jersey Shore University Medical Center.

Click here to watch.

PRIME trial: Biomarker screening cuts NICU admissions in first pregnancies

A biomarker-guided screening strategy significantly reduced neonatal intensive care unit (NICU) admissions and composite neonatal morbidity in nulliparous pregnancies, according to a secondary analysis of the PRIME randomized controlled trial (NCT04301518) published in The Journal of Maternal-Fetal & Neonatal Medicine.

Click here for full study details.

Symptom confusion, care barriers drive perimenopause uncertainty

One in 3 US women aged 35 years and older is uncertain about whether they are in perimenopause, with symptom confusion, knowledge gaps, and barriers to clinical confirmation identified as the primary drivers, according to a large, mixed-methods study published in Menopause, the journal of The Menopause Society.

View the details here.

Highlighting zuranolone's real-world effectiveness on postpartum depression with Joy Baker, MD

A phase 4, prospective, real-world study of zuranolone (Zurzuvae; Sage Therapeutics and Biogen) for postpartum depression (PPD) produced clinically meaningful symptom improvement across all baseline severities, findings that coauthor Joy Baker, MD, FACOG, PMH-C, C-EFM, MT(ASCP), said should increase clinician comfort in prescribing the oral treatment beyond severe disease.

Click here to watch the full discussion with Joy Baker, MD.